Skip Navigation



Cardiovascular Research Advance Access [Accepted Manuscript] published online on February 6, 2009
Cardiovascular Research, doi:10.1093/cvr/cvp037
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
82/1/67    most recent
cvp037v3
cvp037v2
cvp037v1
Right arrow E-letters: Submit a response
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Marshall, M.
Right arrow Articles by Cave, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marshall, M.
Right arrow Articles by Cave, A. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.

Disruption of Protein Phosphatase 2A Contributes to the Cardiac Dysfunction Induced By Endotoxemia

Melanie Marshall, PhD*, Narayana Anilkumar, PhD, Joanne Layland, PhD, Simon J. Walker, BSc, Jonathan C. Kentish, PhD, Ajay M. Shah, MD, FMedSci and Alison C. Cave, PhD

King's College London, Cardiovascular Division, UK

* Corresponding Author: Dr Melanie Marshall, Department of Cardiology, King's College London, James Black Centre, London SE5 9NU, UK. Tel: 0044-20-7848-5359. Fax: 0044-20-7848-5193 E-mail: melanie.marshall{at}kcl.ac.uk

Aims: Sepsis-associated cardiac dysfunction represents an intrinsic impairment of cardiomyocyte function due in part to a decrease in myofilament Ca2+ sensitivity associated with a sustained increase in cardiac troponin I (cTnI) phosphorylation at serines 23/24. Dephosphorylation of cTnI is under regulatory control. Thus, muscarinic and adenosine A1-receptor agonists antagonise β-adrenergic stimulation via activation of protein phosphatase 2A (PP2A). The aim of this study was to determine whether modulation of PP2A and thus cTnI phosphorylation could improve sepsis-induced contractile dysfunction.

Methods: Cardiomyocytes were isolated from control or septic mice 16-18 h after an injection of vehicle or lipopolysaccharide (LPS; 9 mg/kg i.p.) respectively. Protein expression and phosphatase activity was determined in homogenates of control and septic hearts.

Results: LPS significantly increased cTnI phosphorylation at Ser23/24 in cardiomyocytes and reduced contraction amplitude without affecting Ca2+-transients. Treatment of cardiomyocytes with the A1 agonist cyclopentyladenosine (CPA) or the protein kinase A (PKA) inhibitor H89 significantly attenuated the LPS-induced contractile dysfunction without effect on Ca2+-transients. Co-treatment with CPA and H89 completely reversed the contractile dysfunction. Increased cTnI phosphorylation in septic hearts was associated with a significant reduction in the protein expression of both the catalytic and regulatory subunits (B56{alpha}) of PP2A and a decrease in PP2A activity. CPA treatment of septic hearts increased PP2A activity.

Conclusions: This data supports the hypothesis that sustained cTnI phosphorylation underlies the contractile dysfunction seen in sepsis.

KEYWORDS Troponin I; cardiomyocytes; myofilaments; phosphorylation; protein phosphatase 2A

Time for primary review: 23 Days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


E-letters:

Read all E-letters

PP2A activity in sepsis and the importance of the experimental model
Luca Siracusano, et al.
Cardiovascular Research, 30 Mar 2009 [Full text]
Reply to letter by Siracusano & Girasole
Melanie Marshall, et al.
Cardiovascular Research, 23 Apr 2009 [Full text]

Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.